ReviewInfectious diseases and therapy2017
Minocycline for the Treatment of Multidrug and Extensively Drug-Resistant A. baumannii: A Review.
Review in Infectious diseases and therapy, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
45 citing papers in PubMed, 97 citations in OpenAlex.
- Treating Extensively Drug-ResistantPathogens (Basel, Switzerland) · 2026Review
- Minocycline-containing therapy inTherapeutic advances in gastroenterology · 2026Review
- Turning the Tide Against Carbapenem-resistantOpen forum infectious diseases · 2025Article
- "Dusting Off the Cobwebs": Rethinking How We Use New Antibiotics.Antibiotics (Basel, Switzerland) · 2025Review
- Review
- Article
- Population pharmacokinetic model of oral minocycline in critically ill adult patients with ventilator-associated pneumonia.The Journal of antimicrobial chemotherapy · 2025Article
- Chemical genomics informs antibiotic and essential gene function in Acinetobacter baumannii.PLoS genetics · 2025Article
- Bactericidal Effect of a Novel Phage Endolysin Targeting Multi-Drug-ResistantAntibiotics (Basel, Switzerland) · 2025Article
- Whole-genome sequencing ofMicrobial genomics · 2025Article
- Review
- Combinations of Antibiotics Effective against Extensively- and Pandrug-ResistantMicroorganisms · 2024Article
- Designer Small-Molecule Control System Based on Minocycline-Induced Disruption of Protein-Protein Interaction.ACS chemical biology · 2024Article
- Antimicrobial susceptibility and genetic characteristics of multi-drug resistantFrontiers in microbiology · 2024Article
- Antimicrobial Susceptibility Profiles ofVeterinary sciences · 2023Article
- Clinical Effectiveness of Tetracycline-Class Agents Based Regimens in Patients With Carbapenem-ResistantJournal of Korean medical science · 2023Article
- Navigating Available Treatment Options for Carbapenem-Resistant Acinetobacter baumannii-calcoaceticus Complex Infections.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2023Review
- Environmental contamination across multiple hospital departments with multidrug-resistant bacteria pose an elevated risk of healthcare-associated infections in Kenyan hospitals.Antimicrobial resistance and infection control · 2023Article
- Genotyping ofAccess microbiology · 2023Article
- Minocycline and the SPR741 Adjuvant Are an Efficacious Antibacterial Combination forAntibiotics (Basel, Switzerland) · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Acinetobacter baumannii can cause life-threatening nosocomial infections associated with high rates of morbidity and mortality. In recent years, the increasing number of infections due to extensively drug-resistant Acinetobacter with limited treatment options has resulted in a need for additional therapeutic agents, and a renaissance of older, neglected antimicrobials. This has led to an increased interest in the use of minocycline to treat these infections. Minocycline has been shown to overcome many resistance mechanisms affecting other tetracyclines in A. baumannii, including tigecycline. Additionally, it has favorable pharmacokinetic and pharmacodynamic properties, as well as excellent in vitro activity against drug-resistant A. baumannii. Available data support therapeutic success with minocycline, while ease of dosing with no need for renal or hepatic dose adjustments and improved safety have made it an appealing therapy. This review will focus on the mechanisms of action and resistance to tetracyclines in A. baumannii, the in vitro activity, pharmacokinetic and pharmacodynamic properties of minocycline against A. baumannii, and finally the clinical experience with minocycline for the treatment of invasive infections due to this pathogen.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.